# Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

> **NCT05290155** · PHASE1 · COMPLETED · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 14 (actual)

## Conditions studied

- T Lymphoblastic Leukemia/Lymphoma
- T-cell Acute Lymphoblastic Leukemia
- Peripheral T Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** anti-CD7 CAR-T cells

## Key facts

- **NCT ID:** NCT05290155
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-04
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290155, "Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05290155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*